1. Norway Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Medistim ASA

Medistim ASA

27.00
EUR
-0.40
(-1.46%)
0.84EPS
24.51P/E
376.63MMarket Cap
Oct 23Next Earn
Medistim ASA
GETTEX:MD1
(Gettex)

Recent

price

27.00

P/E

ratio

24.51

div

yld

4.59%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
NOK
8.56
8.72
9.97
10.52
11.84
13.8
14.47
16.3
17.77
19.62
19.57
22.94
26.65
28.53
30.72
38.29
41.31
Revenue per Share
1.02
0.85
1.66
1.47
1.73
2.23
2.15
2.62
3.14
3.87
3.81
4.99
6.25
5.68
5.67
8.71
9.5
Basic EPS, GAAP
1.31
0.73
1.08
0.23
1.9
1.81
0.94
2.59
2.17
3.67
3.49
6.36
5.06
4.9
6.47
8.43
8.68
Free Cash Flow per Basic Share
0.9
0.9
1
1.1
0.8
1.4
1.65
1.75
2
2.25
2.75
3
3.75
4.5
4.5
5.99
14.02
Dividend per Share
5.88
5.84
6.28
6.72
7.68
8.61
9.18
10.08
11.37
13.02
14.1
16.79
20.14
21.77
23.84
25.62
22.48
Book Value per Share
4.01
3.88
4.37
4.3
4.99
5.79
6.51
7.74
9.19
10.92
12.31
15.13
18.17
19.29
20.52
20.91
16.32
Tangible Book Value per Share
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
18
Basic Weighted Avg Shares
157
160
182
190
214
250
263
296
323
357
356
418
486
521
563
700
755
Sales/Revenue/Turnover
15.44
14.95
22.6
18.71
20.24
21.2
21.45
22.11
22.9
25.15
26.81
27.83
29.05
25.22
23.3
28.04
28.98
Operating Margin (%)
5
5
6
8
8
13
12
13
12
18
23
23
23
24
15
16
9
Depreciation Expense
19
15
30
27
31
40
39
48
57
70
69
91
114
104
104
159
174
Net Income, GAAP
24.16
30.42
27.38
29.21
30.4
27.36
26.96
28.58
23.39
22.78
24.25
20.31
21.96
23.21
22.66
23.03
22.73
Effective Tax Rate (%)
11.9
9.7
16.62
13.94
14.58
16.17
14.88
16.07
17.66
19.7
19.48
21.76
23.44
19.92
18.46
22.75
22.99
Profit Margin (%)
71
65
65
66
84
94
99
121
135
157
186
229
286
297
322
335
264
Working Capital
- -
- -
- -
5
11
6
2
11
8
27
29
17
10
9
25
38
35
LT Debt
108
107
115
122
139
156
167
183
207
237
257
306
368
398
437
468
411
Total Equity
16.31
14.75
24.78
18.64
19.16
20.43
21.98
22.87
24.81
25.99
23.57
27.39
28.41
23.17
21.04
28.03
36.04
Return on Invested Capital (%)
22.74
14.35
27.3
21.89
22.13
25.15
23.18
25.88
27.66
28.89
24.49
29.18
31.96
26.05
23.5
33.18
37.06
Return on Capital (%)
17.43
14.43
27.24
22.41
23.97
27.38
24.22
27.21
29.28
31.7
28.11
32.3
33.83
27.12
24.88
35.18
39.56
Return on Common Equity (%)

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
38
35
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
4,722
3,823
4,256

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
478
492
387
Cash, Cash Equivalents & STI
206
210
100
Accounts Receivable, Net
86
104
129
Inventories
161
160
156
Total Current Liabilities
143
130
123
Payables & Accruals
- -
- -
- -
ST Debt
12
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.71%
12.91%
7.28%
Free Cash Flow
29.83%
24.31%
30.12%
Net Income, GAAP
16.11%
20.16%
53.33%
Sales/Revenue/Turnover
11.04%
14.64%
24.38%
Total Cash Common Dividend
16.11%
17.52%
32.82%

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
134
145
133
151
563
2025
182
169
- -
182
700
2026
202
202
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.33
1.9
1.28
1.16
5.67
2025
2.37
2.35
- -
2.08
8.71
2026
2.2
2.85
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.5
2025
- -
6.02
- -
- -
5.99
2026
- -
8
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medistim ASA develops, manufactures, services, leases and distributes medical devices that combine transit time flow measurement (TTFM) and high-frequency ultrasound imaging for cardiac, vascular and transplant surgery; its core products include the MiraQ Cardiac system for cardiac surgery, MiraQ Vascular for vascular and transplant procedures, MiraQ Ultimate for both cardiac and vascular applications, MiraQ INTUI software platform with intuitive controls, and associated imaging probes for intraoperative blood flow assessment and visualization of atherosclerosis. Founded in 1984 and headquartered in Oslo, Norway, the company serves surgeons and hospitals in the United States, Europe, Asia and other international markets, focusing on quality assurance to enhance surgical outcomes and reduce risks. In recent developments, Medistim strengthened its commercial operations in January 2025 by appointing a chief commercial officer and a new vice president of sales for the Americas; it launched the clinical PATENT study in November 2024 to evaluate TTFM and high-frequency ultrasound benefits in vascular surgery; the company introduced the MiraQ INTUI software platform following a successful early access program, with official rollout at the International Coronary Congress in December 2024; it also hosted a Capital Markets Day in December 2024 and reported record sales revenues, including 25.8% growth to MNOK 350.6 for the first half of 2025.